The study, reported on by Gastroenterology & Endoscopy News, used a model to assess the cost effectiveness of screening 40-year-old patients via either colonoscopy, flexible sigmoidoscopy, fecal occult blood test, fecal immunochemistry test or fecal immunochemical DNA test. Researchers measured incremental cost-effectiveness ratio.
Researchers said each test option was cost-effective. Flexible sigmoidoscopy was the cheapest option at $3,284 per person, while fecal immunochemical DNA testing was the most expensive option at $11,532 per person.
While researchers were hesitant to recommend patients start screening at 40 years old, they did suggest the model should be considered in future model refinement.
More articles on healthcare:
Top-paying jobs in 2020 — Surgeons are No. 1
The state of ASCs in June 2020: 10 observations on supply chain, payers, staffing & future growth
Optum leads $26M funding round for digital therapeutics startup
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.